成人に対する完全埋め込み型人工内耳(TICI)システムの臨床的有益性、性能、安全性を評価するための重要な研究 (ELEVATE)
感音難聴を有する成人集団におけるTI1132インプラントの臨床的便益、性能、安全性を評価するための、重要な、上市前、前向き、介入型、多施設共同研究
This pivotal study examines the clinical efficacy and safety of an investigational totally implantable cochlear implant (TICI) system. The system includes a microphone placed under the skin to detect speech and sound from the environment, providing the option to hear without any visible external parts. This study will involve adults with sensorineural hearing loss, a type of hearing loss caused by damage to the inner ear or auditory nerve (the nerve that carries sound signals from the ear to the brain). Participants will complete hearing tests and questionnaires to evaluate how well the system works and how it affects their daily life.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究場所
-
-
Colorado
-
Englewood、Colorado、アメリカ、80113
- Rocky Mountain Ear Center
-
-
Florida
-
Miami、Florida、アメリカ、33136
- University of Miami School of Medicine
-
-
Iowa
-
Iowa City、Iowa、アメリカ、52242
- University of Iowa
-
-
Michigan
-
Novi、Michigan、アメリカ、48374
- Michigan Ear Institute
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55902
- Mayo Foundation Rochester
-
-
Missouri
-
Kansas City、Missouri、アメリカ、64111
- Midwest Ear Institute
-
St Louis、Missouri、アメリカ、63108
- Washington University School of Medicine
-
-
New York
-
New York、New York、アメリカ、10017
- NYU Langone Health
-
-
Ohio
-
Beachwood、Ohio、アメリカ、44122
- University Hospitals Cleveland Medical Centre
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73120
- Hearts for Hearing Foundation
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84132
- University of Utah Hospitals and Clinics
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Individuals aged 18 years and older at time of consent.
- Clinically established sensorineural hearing loss (SNHL) defined by a four frequency (500, 1000, 2000, 4000 Hz) pure-tone average unaided threshold (PTA4) of ≥70 dB HL in the ear to be implanted.
- Compromised functional hearing in the aided condition defined as ≤40% correct on a word recognition test in the ear to be implanted.
- Clinically established SNHL defined by a four-frequency (500, 1000, 2000 & 4000 Hz) pure-tone average unaided threshold (PTA4) of ≥30 dB HL in the contralateral ear.
- Candidate is a fluent speaker in the language used to assess speech perception performance as determined by the investigator.
- Direct access to a compatible Smart Phone.
- Willing and able to provide written informed consent.
Exclusion Criteria:
- Prior cochlear implantation, in either ear, or medical plan for cochlear implantation during the clinical investigation, contralateral to the ear to be implanted.
- Candidates with single-sided deafness as determined by the investigator.
- Intra-axial (within-the-brain) lesions or deafness due to lesions of the acoustic nerve affecting the ear to be implanted.
- Middle ear infection (including acute otitis media, chronic otitis media, suppurative otitis media, or serous drainage) in the ear to be implanted either at the time of surgery or within 3 months prior to enrolment.
- Presence of a tympanic membrane perforation or a history of otologic surgery within 3 months prior to enrolment, in the ear to be implanted.
- Previously reported diagnosis of auditory neuropathy, in the ear to be implanted.
- Ossification, malformation or any other cochlear anomaly, such as common cavity, that might prevent complete insertion of the electrode array, in the ear to be implanted.
- Current cerebrospinal fluid (CSF) shunts or drains, existing perilymph fistula, skull fracture or CSF leaks.
- Severe, or poorer, bilateral sensorineural hearing loss prior to 5 years of age, as reported by the participant.
- Severe, or poorer, sensorineural hearing loss for more than 20 years, as reported by the participant, in the ear to be implanted.
- Medical or psychological conditions that contraindicate general anaesthesia, surgery, or participation in the clinical investigation as determined by the investigator.
- Pre-existing skin condition that could jeopardize wound healing as judged by the investigator e.g., psoriasis, dermatitis, use of corticosteroids, uncontrolled diabetes.
- Unrealistic expectations on the part of the participant, regarding the possible benefits, risks, and limitations inherent to the surgical procedure(s) and prosthetic devices, as determined by the Investigator.
- Additional disabilities that may affect the participant's participation or safety during the clinical investigation.
- Unable or unwilling to comply with all requirements of the clinical investigation, as determined by the investigator.
- Pregnant or breastfeeding women.
- Investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as spouse, parent, child or sibling.
- Cochlear employees or employees of Contract Research Organisations or contractors engaged by Cochlear for the purposes of the investigation.
- Current participation, or participation in another interventional clinical study/trial in the past 30 days, involving an investigational drug or device (unless Cochlear sponsored and determined by Investigator or Sponsor to not impact this investigation).
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Totally Implantable Cochlear Implant System
Participants will be implanted with the TI1132 implant |
Totally Implantable Cochlear Implant System |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Speech recognition performance in quiet
時間枠:Preimplantation to 6-months post-activation
|
Percent correct scores in word recognition score from pre-implantation to post-implantation. |
Preimplantation to 6-months post-activation
|
|
Incidence of adverse events and device deficiencies
時間枠:Implantation to 6- and 12-months post-activation
|
Frequency and severity of device and procedure-related adverse events, including device deficiencies. |
Implantation to 6- and 12-months post-activation
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Speech, Spatial and Qualities of Hearing questionnaire (SSQ-12)
時間枠:Preimplantation to 6- and 12-months post-activation
|
Speech, Spatial, and Qualities of Hearing Scale global score (SSQ-12). Scores range from 0 to 10, where higher scores indicate greater ability (less hearing disability). |
Preimplantation to 6- and 12-months post-activation
|
|
Speech recognition performance in noise
時間枠:Preimplantation to 6- and 12-months post-activation
|
Percent correct sentence score from preimplantation to 6- and 12-months post-activation. |
Preimplantation to 6- and 12-months post-activation
|
|
Speech recognition performance in quiet
時間枠:Preimplantation to 12-months post-activation
|
Percent correct word recognition score in quiet from pre-implantation to post-implantation. |
Preimplantation to 12-months post-activation
|
|
Cochlear Implant Quality of Life Profile (CIQOL-35)
時間枠:Preimplantation to 6- and 12-months post-activation
|
Cochlear implant hearing related quality of life score (CIQOL-35). Scored for six health domains (communication, emotional, entertainment, environment, listening effort, and social) each scaled from 0 to 100, where a higher score indicates better health. |
Preimplantation to 6- and 12-months post-activation
|
|
Health Utilities Index (HUI 2/3)
時間枠:Preimplantation to 6- and 12-months post-activation
|
Health Utilities Index (HUI 2/3) global score. Scores range from -0.36 to 1.00, where a negative score represents a state "worse than dead" and a top score of 1.00 is "perfect health". |
Preimplantation to 6- and 12-months post-activation
|
|
Living with Cochlear Implants Questionnaire (LivCI)
時間枠:Preimplantation to 6- and 12-months post-activation
|
Living with Cochlear Implants Questionnaire (LivCI) evaluates the impact of a hearing device on four domains, Participation (range 0 to 12), Psychosocial & Wellbeing (range 0 to 21), Stigma (range 0 to 15) and Management & Aesthetics (range 0 to 18), where a higher domain score indicates positive patient report. |
Preimplantation to 6- and 12-months post-activation
|
|
Patient Satisfaction Survey
時間枠:From 6 to 12 months post-activation
|
Device satisfaction rating score. Scores range from 1 to 5, where a higher score indicates greater patient satisfaction with the TICI system. |
From 6 to 12 months post-activation
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Craig Buchman、University of Utah
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- CLTD5828
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。